HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Waits For NDI Notifications Increase On Tail Of 'No Objection' Uptick

This article was originally published in The Rose Sheet

Executive Summary

FDA has seen an uptick in “acknowledgement with no objection” response letters to dietary supplement firms' s NDI notifications, but says those positive responses still account for only a quarter of all its responses.

You may also be interested in...



Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting

FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.

‘Old’ Ingredient List On FDA Table Could Spur New Supplement Launches

CFSAN schedules a public meeting on developing a list of dietary ingredients available in the food supply before Congress in 1994 passed DSHEA. CRN expects the meeting to lead an “official safe harbor list” of eligible ingredients, but not directly to a final NDI notifications guidance.

Making Nutritionals Eligible For Health Savings Accounts Whets Congress' Appetite

The supplement Industry and members of Congress open a line of communication on including dietary supplements into FSA/HSA spending programs, says CRN President Steve Mister.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS109246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel